Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Taehyung Kim, Daniela Žácková, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Young Seok Yoo, Hyewon Lee, Kyoung Ha Kim, Myung Hee Chang, Seong Yoon Yi, Jessie J.F. Medeiros, Sagi Abelson, Dennis Kim

Blood (2022) 140 (Supplement 1): 812–814.

https://doi.org/10.1182/blood-2022-162676

Published: 2022

Journal Articles

Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease

Alistair Murray, Swe Mar Linn, Benoit Yu, Igor Novitzky-Basso, Jonas Mattsson, Mohamed Elemary, Jennifer White, Christopher Lemieux, Kareem Jamani, Dennis Kim

Blood (2022) 140 (Supplement 1): 7662–7663.

https://doi.org/10.1182/blood-2022-164874

Published: 2022

Journal Articles

Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine

Mihee Kim, Taehyung Simon Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, MiYeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Kim

Blood (2022) 140 (Supplement 1): 6094–6095.

https://doi.org/10.1182/blood-2022-164916

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Wilson Lam, MD, Arjun Datt Law, MBBS, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Theodore Marras, MD MSc, Shikha Mittoo, MD MHS, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1973.

https://doi.org/10.1182/blood.V130.Suppl_1.1973.1973

Published: 2017

Journal Articles

Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Shun Liao, Taehyung Kim, MSc, Hyeoung-Joon Kim, Jae-Sook Ahn, Jaehyuk Choi, Yeo-Kyeoung Kim, Yoon-Sang Kim, Seung-Shin Lee, MD, Zhaolei Zhang, PhD, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1599.

https://doi.org/10.1182/blood.V130.Suppl_1.1599.1599

Published: 2017

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Ali Alahmari, MD, Jeffrey H. Lipton, MD PhD, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 2880.

https://doi.org/10.1182/blood.V130.Suppl_1.2880.2880

Published: 2017

Journal Articles

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

Blood (2015) 126 (6): 746–756.

https://doi.org/10.1182/blood-2015-03-636548

Published: 2015

Includes: Supplemental data

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

Marc Poch Martell, MD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Jeffrey H. Lipton, MD PhD, John Kuruvilla, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD, Dennis Kim, MDPhD

Blood (2014) 124 (21): 3936.

https://doi.org/10.1182/blood.V124.21.3936.3936

Published: 2014

Journal Articles

HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival

Marc Poch Martell, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Fotios V. Michelis, MDPhD, Jieun Uhm, MD, Feras Alfraih, MD, Mohamed Shanavas, MD FRACP, FRCPA, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis Kim, MDPhD

Blood (2014) 124 (21): 3915.

https://doi.org/10.1182/blood.V124.21.3915.3915

Published: 2014

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning

Nada Hamad, MBBS Hons, FRACP, FRCPA, Ryan Del Bel, B.Math, Hans A. Messner, M.D./Ph.D, Dennis Kim, MD, John Kuruvilla, MD, Jeffrey H. Lipton, MD, PhD, Jieun Uhm, MD, Wei Xu, Vikas Gupta, MD, FRCP, FRCPath

Blood (2013) 122 (21): 2044.

https://doi.org/10.1182/blood.V122.21.2044.2044

Published: 2013

Journal Articles

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

Naheed Alam, MBBS, Eshetu G Atenafu, MSc, Wei Xu, Ph.D., Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD, PhD

Blood (2013) 122 (21): 4613.

https://doi.org/10.1182/blood.V122.21.4613.4613

Published: 2013

Journal Articles

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Jieun Uhm, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD

Blood (2013) 122 (21): 3289.

https://doi.org/10.1182/blood.V122.21.3289.3289

Published: 2013

Journal Articles

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, Dennis Kim, MD

Blood (2013) 122 (21): 3303.

https://doi.org/10.1182/blood.V122.21.3303.3303

Published: 2013

Journal Articles

A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia

Dong Hwan (Dennis) Kim, Seung-Tae Lee, Hong-Hee Won, Seonwoo Kim, Min-Ji Kim, Hee-Jin Kim, Sun-Hee Kim, Jong-Won Kim, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Sang Kyun Sohn, Joon Ho Moon, Chul Won Jung, Jeffrey H. Lipton

Blood (2011) 117 (25): 6906–6911.

https://doi.org/10.1182/blood-2011-01-329797

Published: 2011

Includes: Supplemental data

NARROW

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease

Prognostic Analysis According to European Leukemianet 2022 Risk Stratification for Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival

Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation

A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only